Equities

Shanghai Haixin Group Co Ltd

Shanghai Haixin Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.211
  • Today's Change-0.003 / -1.40%
  • Shares traded653.35k
  • 1 Year change-29.19%
  • Beta--
Data delayed at least 15 minutes, as of Sep 23 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Shanghai Haixin Group Co Ltd had little change in net income (from 164.06m to 166.03m) despite revenues that fell -17.88% from 1.44bn to 1.18bn.
Gross margin49.64%
Net profit margin20.39%
Operating margin21.82%
Return on assets3.93%
Return on equity4.22%
Return on investment4.50%
More ▼

Cash flow in CNYView more

In 2023, Shanghai Haixin Group Co Ltd increased its cash reserves by 15.55%, or 65.36m. Cash Flow from Investing totalled 158.78m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 35.88m for operations while cash used for financing totalled 57.82m.
Cash flow per share--
Price/Cash flow per share--
Book value per share3.22
Tangible book value per share3.21
More ▼

Balance sheet in CNYView more

Shanghai Haixin Group Co Ltd uses little debt in its capital structure as supported by a debt to capital ratio of 2.02%.
Current ratio2.61
Quick ratio2.44
Total debt/total equity0.0215
Total debt/total capital0.0202
More ▼

Growth rates in CNY

SmartText is unavailable
Div yield(5 year avg)0.57%
Div growth rate (5 year)13.18%
Payout ratio (TTM)47.23%
EPS growth(5 years)4.20
EPS (TTM) vs
TTM 1 year ago
18.26
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.